Date: 2014-12-03
Type of information: Licensing agreement
Compound: peptides derived from IGFBP-2 (Insulin-like Growth Factor Binding Protein-2)
Company: Alize Pharma (France) New Paradigm Therapeutics (USA - NC)
Therapeutic area: Bone diseases
Type agreement: licensing
Action mechanism:
Disease: bone loss
Details: * On December 3, 2014, Alizé Pharma III SAS, an Alizé Pharma group company specialized in the development of biopharmaceuticals to treat metabolic disorders and rare diseases, announced that it has acquired exclusive worldwide rights to develop and commercialize a new family of peptides with bone anabolic properties. The peptides are derived from a fragment of a physiological protein, called IGFBP-2 (Insulin-like Growth Factor Binding Protein-2). In vitro and in vivo studies showed the peptides’ ability to induce bone formation by stimulating osteoblast differentiation and inhibiting osteoclast differentiation.
Alizé Pharma III SAS is a new company, created for this project. It was set up to select a drug candidate based on a lead optimization program
and advance it to the clinical stage The inventors of the IGFBP-2- based technology are Dr. David Clemmons, chief of the division of endocrinology and metabolism, School of Medicine, University of North Carolina at Chapel Hill and Dr. Clifford Rosen, the director of clinical and translational research, and a senior staff scientist at Maine Medical Center’s Research Institute (Portland, ME).
The University of North Carolina and the University of Maine own the patent on the IGFBP-2 peptides. The patent was originally licensed to New
Paradigm Therapeutics Inc. (NPT Inc.), a University of North Carolina spin-off company founded by Dr. Clemmons. NPT Inc. has granted an exclusive sublicense to Alizé Pharma III SAS. Both companies will now collaborate on the development of a new therapy targeting bone diseases.
=
Financial terms: According to the terms of the agreement, Alizé Pharma III SAS will pay NPT Inc. an agreed percentage of its licensing or divestment revenues.
Latest news:
